Ras CAAX (C = cysteine, A = aliphatic amino acid, and X = any amino acid) peptidomimetic inhibitors of farnesyl protein transferase suppress Ras-dependent cell transformation by preventing farnesylation of the Ras oncoprotein. These compounds are potential anticancer agents for tumors associated with Ras mutations. The peptidomimetic FTI-254 was tested for Rasl-inhibiting activity in whole animals by injection of activated Raslval2 Drosophila larvae. FTI-254 decreased the ability of RaslvaIl2 to form supernumerary R7 photoreceptor cells in the compound eye of transformed flies. In contrast, it had no effect on the related supernumerary R7 phenotypes of flies transformed with either the activated sevenless receptor tyrosine kinase, Raf kinase, or a chimeric RaslvaI12 protein that is membrane associated through myristylation instead of isoprenylation. Therefore, FTI-254 acts as an isoprenylation inhibitor to selectively inhibit Raslva1l2 signaling activity in a wholeanimal model system. Ras proteins are membrane bound GTP-binding proteins that transduce mitogenic signals from receptor tyrosine kinases (RTKs) to the nucleus (1). Certain mutations in Ras genes produce constitutively activated products resulting in deregulated growth control. Mutations in RAS genes are linked to 50% of human colon carcinomas and >90% of human pancreatic carcinomas (2). Association of Ras with the membrane is essential for Ras-induced cell transformation and is mediated through a covalently linked isoprenyl group (3-6). Isoprenylated proteins, such as Ras, share a carboxyl-terminal CAAX sequence (C = cysteine, A = aliphatic amino acid, and X = any amino acid), and the isoprenyl group is transferred to the sulfhydryl moiety of the cysteine residue from an isoprenyl diphosphate donor (7, 8 
kinase, or a chimeric RaslvaI12 protein that is membrane associated through myristylation instead of isoprenylation. Therefore, FTI-254 acts as an isoprenylation inhibitor to selectively inhibit Raslva1l2 signaling activity in a wholeanimal model system. Ras proteins are membrane bound GTP-binding proteins that transduce mitogenic signals from receptor tyrosine kinases (RTKs) to the nucleus (1). Certain mutations in Ras genes produce constitutively activated products resulting in deregulated growth control. Mutations in RAS genes are linked to 50% of human colon carcinomas and >90% of human pancreatic carcinomas (2) . Association of Ras with the membrane is essential for Ras-induced cell transformation and is mediated through a covalently linked isoprenyl group (3) (4) (5) (6) . Isoprenylated proteins, such as Ras, share a carboxyl-terminal CAAX sequence (C = cysteine, A = aliphatic amino acid, and X = any amino acid), and the isoprenyl group is transferred to the sulfhydryl moiety of the cysteine residue from an isoprenyl diphosphate donor (7, 8) . Three enzymes are known to catalyze protein isoprenylation: farnesyl protein transferase (FPTase), geranylgeranyl protein transferase I (GGPTase I), and geranylgeranyl protein transferase II (GGPTase II). The identity of the carboxyl amino acid of the CAAX sequence specifies enzyme recognition by FPTase or GGPTase I, whereas GGPTase II recognizes an XXCC or XCXC sequence motif. Posttranslational modification of mammalian Ras includes the attachment of a 15-carbon farnesyl moiety by the FPTase enzyme (9, 10) . FPTase recognizes and farnesylates peptides as short as four amino acids provided they consist of the Ras CAAX consensus sequence (7) . Thus, CAAX tetrapeptides serve as alternative substrates for farnesylation in vitro and can competitively inhibit farnesylation of Ras (9) (10) (11) (12) (13) (14) . CAAX-based peptidomimetics designed to inhibit FPTase block Ras modification in cell culture and have antiproliferative activities against Ras-transformed cells both in cell culture and in nude mice (15) (16) (17) (18) (19) (20) (21) 38) . Furthermore, these compounds selectively inhibit Ras-induced phenotypes in several assays even though they reduce farnesylation of other proteins (14) .
However, the specificity of CAAX peptidomimetics for inhibiting oncogenic Ras Larval Microinjection. Wandering third-instar larvae were immobilized on a microscope slide with double-stick tape and partially anesthetized by exposure to Fly-Nap (Carolina Biological Supply) for 15 min. Before injection, the larvae were covered with Halocarbon oil (Halocarbon Products, Hackensack, NJ). Glass injection needles pulled to an average diameter of 10 ,um delivered -3 nl of the peptidomimetic into the hemocoelic cavity at the third thoracic larval segment. A specific injection location is not essential since random injections along the larvae had no effect on the ability of the peptidomimetic to suppress the activated phenotype. The average injection volume was determined from micrometer measurements. After injection, larvae were removed from the tape and placed in standard food until eclosion. Working stock solutions of peptidomimetics were 100 mM peptidomimetic/10 mM dithiothreitol (DTT) in dimethyl sulfoxide (DMSO) and were further diluted with 1 mM DTT. Untreated third instar larvae remained in food vials until eclosion and did not undergo manipulation.
GGPTase I Assays. Geranylgeranyl modification of Ha-Ras-CVLL by mammalian GGPTase I in vitro was assayed as described (21) . IC50 values for each peptidomimetic were determined by assaying GGPTase I activity at multiple concentrations of peptidomimetic.
RESULTS AND DISCUSSION Ras CAAX Peptidomimetic Treatment Rescues the RaslvaIl2 Phenotype. Drosophila transgenic lines bearing the dominant activating Raslvall2 mutation (25) were used to evaluate the effect of a series of CAAX peptidomimetics ( Fig. 1 ) on the transforming activity of Rasl in the compound eye. Raslvall2 gene activity causes a severe roughening of the external surface of the eye (compare Fig. 2A and B), and sections through eyes reveal multiple R7 cells per facet or ommatidium (compare Fig. 2 F and G). We injected a single dose of peptidomimetic FTI-244 into RaslvalJ2 larvae and examined the eye phenotypes of treated individuals following pupation. FTI-244 is carboxylmethylated to facilitate cellular uptake and inhibits Ras processing in cell culture (33) . There was significant suppression of the external eye phenotype, suggesting that this compound reduced Raslvall2 activity (Fig. 2C) . We treated lines with a related compound, FTI-232, which is a potent FPTase inhibitor in vitro but is unable to inhibit FPTase in cell culture due to membrane impedance associated with a free carboxylate group (21, 33) . We injected FTI-232 into Raslvall2 larvae and observed no suppression of the rough-eye phenotype (Fig. 2D) , consistent with the observation that FTI-232 does not inhibit Ras activity in cell culture. FTI-254, a more potent analog of FTI-244 (21) , was also tested by injection into RaslvaIl2 larvae.
A suppression of the rough-eye phenotype similar to that seen with FTI-244 was observed (Fig. 2E) . Sections through these eyes revealed an almost complete suppression of the Raslvall2 phenotype; most ommatidia contain one R7 cell rather than the two or three evident in untreated animals (Fig. 2H) .
Since (Fig. 3A) . Flies injected with 20 mM FTI-254 (60 pmoles) exhibited a significant downward shift in their distribution among the four classes, and 30% of the flies created a new phenotypic class with an average of almost one R7 cell per ommatidium (Fig. 3A) . The ium from 2.1 to 2.0 (Fig. 3B) . The reduction may be due to other isoprenylated proteins, possibly Rasl itself, contributing to R7 cell differentiation. However, comparison of FTI-254 treatment of Raslvall2 and RasMYr flies demonstrates the specificity of FTI-254 for inhibiting isoprenyl modification of Rasl in whole animals.
The Ras CAAX Peptidomimetics Specifically Suppress Rasl. To evaluate the selectivity of FTI-254 for Rasl inhibition, we assayed the effect of FTI-254 on supernumerary R7 cell formation in flies transformed with either an activated sevenless, Raf, or rolled MAP kinase gene. None of these gene products are modified by isoprenylation. In addition, they function within the same signal transduction pathway as Rasl to trigger R7 cell differentiation (23) . The sevenless RTK functions upstream of Rasl while Raf and rolled function downstream of Rasl in the pathway. Activated forms of sevenless (Sevs1) (24) , Raf (sE-raf'Or402l) (26) , and rolled (sev-Sem) produce a similar phenotype to Raslvall2 with supernumerary R7 cell formation (Fig. 2 J-L) . Injection of 40 mM FTI-254 into Sevs] and sE-raf'or4021 larvae had no effect on supernumerary R7 cell formation (Fig. 2 M and N; Fig. 3C ).
This suggests that FTI-254 is highly specific for RaslvaIl2_ transformed cells. It further suggests that normal Rasl activity is not significantly affected by FIl-254 in the ectopic R7 cells transformed by Sevs1 since normal Rasl activity is required for transformation by Sevs1 (R.W.C., unpublished data).
Because the number of supernumerary R7 cells did not decrease after injection, it also rules out the possibility that transformed cells are more sensitive to cytotoxic effects of FTI-254 treatment. Injection of 40 mM FTI-254 into sev-Sem larvae partially rescued the eye phenotype (Fig. 20) (7) . Indeed, evidence suggests that Drosophila Rasl is geranylgeranylated. The C-terminal amino acid of Rasl is leucine, which normally serves as a substrate for GGPTase I (1, 7, 8) . Moreover, null mutations in the Drosophila GGPTase I gene suppress the Raslvall2 phenotype in a dosage-dependent manner (28) . Therefore, to confirm that the Raslvall2 protein is an in vivo substrate for GGPTase I, we injected RaslvaIl2 larvae with peptidomimetics that exhibit different potencies for inhibiting GGPTase I. The in vitro IC50 values for inhibition of GGPTase I by various peptidomimetics were determined (Table 1) . FTI-254 was more potent than FTI-265 in inhibiting GGPTase I but was less effective than FPI-280. FPI-265 is a nonpeptide CAAX mimetic with the tripeptide AAX replaced by a biphenyl derivative (Fig. 1) . FPI-280 is identical to FTI-254 except for a Leu residue at the carboxyl position (Fig. 1) . Injection of 40 mM FTI-265 into RaslvaIl2 larvae was less effective than injection of 20 mM FTI-254 in suppressing supernumerary R7 cell formation (Fig.  3D) . Injection of 20 mM FII-280 into RaslvaIl2 larvae was more effective than injection of 40 mM FIl-254 at suppressing supernumerary R7 cell formation (Fig. 3A and D) . Moreover, FTI-254 suppressed the Raslvall2 phenotype when 120 pmoles was injected into larvae. Assuming uniform distribution of the compound in each larva, this corresponds to a whole-body concentration of 40 ,tM, above its in vitro IC50 value for GGPTase I. Taken together, these data support previous evidence that RaslvaIl2 is geranylgeranylated and correlates in vitro GGPTase I inhibitory activities of the peptidomimetics with their ability to suppress the Raslvall2 phenotype in vivo.
To investigate the effect of the peptidomimetics on other members of the Ras superfamily of GTPases, we treated Roughened larvae with FIl-280. Roughened is an activated mutant allele of the Drosophila homolog of RaplA (35) Suppression of ectopic R7 cell transformation by injection of Ras CAAX peptidomimetics into RaslvalI2qtransformed larvae (A and D), RasMYr-transformed larvae (B), or sE-raftor402I-transformed larvae (C). Larvae were either injected with the indicated concentration of peptidomimetic or received no treatment. For each transformed line, the flies that eclosed were classified into different groups according to the severity of their rough-eye phenotypes. Approximately 12 flies were randomly chosen from each group, and their eyes were sectioned tangentially. Only the anterior-most region of the eye was sectioned and analyzed because of the nonuniformity of the supernumerary R7 cell phenotype across the surface of the eye. For each group, a total of 400 ommatidia were scored to determine the average number of R7 cells per ommatidium. The mean values for each group are indicated along the horizontal axis and are plotted against the number of flies placed within that group. Groups were delineated such that the standard deviation from the mean number of R7 cells per ommatidium in each group was less than 10%. A total of 100 flies were examined for each peptidomimetic concentration injected.
Roughened protein is likely geranylgeranylated since its Cterminal residue is leucine, and its mammalian homolog is geranylgeranylated (35, 36) . Injection of 20 mM FTI-280 suppressed the rough-eye phenotype of Roughened (R.C.K., unpublished data). Thus, other activated GTPases that are dependent upon isoprenylation can be inhibited by CAAX peptidomimetics in vivo.
The Ras CAAX Peptidomimetics Have a Low Level of Toxicity. Comparison of various peptidomimetics in vitro suggest they have a 10-to 100-fold increased specificity for inhibiting their cognate enzymes (21) . Because the peptidomimetic concentrations injected in these experiments were probably sufficient to affect both farnesylated and geranylgeranylated proteins, we examined the general cytotoxicity of FTI-254 by measuring lethality of animals injected with various doses of the peptidomimetic (Fig. 4) . Although increasing doses of FTI-254 resulted in lower viability, part of this effect was due to the presence of the carrier solvent, DMSO, which by itself caused significant lethality. At 40 mM, the lethal effect of FTI-254, compared with the DMSO control, was statistically insignificant. Furthermore, injected animals examined for 
